Protocol for Management of Peritoneal Dialysis-Related Infections in Sudan by Elhassan, E
Arab Journal of Nephrology and Transplantation
33
* Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes 
C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, 
Ramos A, Schaefer F, Uttley L; ISPD Ad Hoc Advisory Committee.
Peritoneal dialysis-related infections recommendations: 2005 update. 
Perit Dial Int 2005 Mar-Apr;25(2):107-31. 
** Corresponding author; Division of Renal Diseases and Hypertension, 
University of Colorado Health Sciences Center, P.O.Box 6508, Aurora, 
CO 80045, USA.
E mail: Elwaleed.Elhassan@UCHSC.edu
Protocol for Management of Peritoneal Dialysis-Related Infections in Sudan
Adapted from the International Society for Peritoneal Dialysis (ISPD) Peritoneal Dialysis-Related Infections Recommendations: 2005 Update *
Approved by the Sudan Peritoneal Dialysis Program
Elwaleed AM Elhassana**
a. MD, Sudan Peritoneal Dialysis Program
Arab Journal of Nephrology and Transplantation
Clinical Guidelines AJNT
Introduction
Peritonitis is one of the major risks of peritoneal dialysis 
(PD), causing significant morbidity and sometimes 
mortality. It is also one of the principal causes of 
technique failure. Prevention of peritonitis is one of the 
keys to success with PD.
Goals and targets
To ensure standardization of management of PD-related • 
peritonitis between all units of the Sudan PD program 
(Sudan-PD).
To achieve a peritonitis rate of no more than 1 episode • 
every 18 months at risk (0.67 per year at risk) in all 
units of the Sudan-PD, by adopting effective preventive 
measures and by proper management of PD catheter 
exit site infections.
To promot timely diagnosis and proper management • 
of peritonitis in order to decrease its complications 
(catheter loss, technique failure and death).
Recommendations
Prevention of PD related peritonitis
Prior to PD catheter insertion, take a nasal swab culture • 
for Staph aureus; if positive, instruct the patient to apply 
mupirocin nasal ointment three times daily for 5 days.  
Regardless of technique, PD catheter placement must • 
take place under strict aseptic conditions, using face 
masks, gowns and sterile gloves. 
Give a single dose of prophylactic antibiotic one hour • 
before the procedure; use a first or second generation 
cephalosporin (e.g. cefazolin, cefuroxime).  
A two cuffed PD catheter should be used for all patients. • 
The inner cuff must be placed within or below the rectus 
muscle to provide structural support for the catheter. 
The superficial cuff should be placed at least 2 cm deep 
to the exit site. The subcutaneous tunnel must have a 
downward (or if necessary lateral) direction, and the 
exit site must be created with a puncture hole rather than 
a scalpel to produce a tight fit around the catheter and 
avoid the use of sutures. The exit site should be placed 
in a location that is easily accessible to the patient for 
future care. It should not be placed on the belt line, on a 
scar or under an abdominal hang in obese patients.
After implantation, the exit site should be covered with • 
several layers of sterile gauze; avoid transparent and 
occlusive dressings because drainage tends to pool at 
the exit site and in the wound therefore encouraging 
bacterial overgrowth. Instruct the patient to keep the 
dressing dry and clean. Sponge bathing may be used 
for 2-3 weeks until the exit site is well-healed. The 
dressing should be changed after one week unless there 
is obvious bleeding or signs of infection, or sweating 
that makes the exit site wet, or the patient feels itchy 
under the taped skin, or if the stickiness of the tape is 
lost. Dressing changes should be restricted to trained 
nurses under aseptic conditions using face masks and 
sterile gloves.
The double bag system and • the flush before fill 
technique should be used for all patients. Adequate 
patient training reinforced by home visits is an effective 
tool in reducing PD-related infections. 
Aseptic technique should be practiced every time the • 
catheter or exit site is handled. This includes proper 
hand washing, proper preparation of the work area, and 
proper handling of equipment and supplies
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Proper hand washing•  refers to scrubbing the hand for 
at least 15-20 seconds with the six steps method, using 
clean tap water and antibacterial soap. If tap water 
is contaminated or is coming from a well, bottled or 
boiled water should be used instead. If liquid soap is 
not available, a soap bar can be used. If soap and water 
are not available, an alcohol-based cleansing agent that 
contains at least 60% isopropanol or ethanol should be 
used instead. 
If a cleansing agent is used for hand washing, sufficient • 
amounts should be used to wet the hands all over, 
followed by scrubbing the hand with the six steps 
method without using a towel to dry the hands. If hands 
are dry in less than 15 seconds, the user has not applied 
enough amount of sanitizer. Cleanser type may be 
individualized based upon allergies, but it should not 
be transferred to another container because of the risk 
of contamination. 
Exchanges and exit site care should be performed in a • 
clean room, with the doors and windows closed and the 
fans turned off. There should be no animals in the room. 
Supplies should be collected on a clean table.
The tips of the transfer set and the Y-shaped giving • 
set should not touch anything while performing the 
exchanges. If the end of the Y-shaped giving set is 
contaminated, the double bag must be discarded and a 
new set used instead. If the end of the transfer set is 
contaminated, the patient must not continue with the 
exchange and he/she must present to the center for 
transfer set changing. Prophylactic antibiotics should 
be prescribed for two days in case of transfer set 
contamination. 
If medications are to be infused into the medication port • 
of the bag, povidone iodine should be applied to the 
port until it dries and the tip of the syringe should not be 
allowed to touch anything. 
The PD catheter and transfer set should remain securely • 
taped to the abdomen at all times to minimize trauma. 
Some patients may use a belt or immobilizer. When 
securing the PD catheter, ensure that the catheter follows 
its natural direction and does not bend at its connection 
to the adapter, as the catheter can crack over time and 
this puts the patient at risk for getting peritonitis.
Tub baths should not be taken with a PD catheter in place • 
to avoid contamination with water borne organisms. 
Showers may be taken once the exit site is well healed, 
but the patient must avoid scrubbing the exit site. After 
showers, the exit site should be dried first with a clean 
personal towel, then the rest of the body.
Routine exit site care should be done daily by the patient • 
and after each shower. For cleaning the exit site care, 
it is preferred to use a piece of gauze saturated with 
normal saline, followed by the application of iodine 
and prophylactic gentamicin cream. Crusts should not 
be forcibly removed, and the exit site should never 
be handled with sharp instruments. If the exit site is 
well healed there is no need to cover it with gauze in 
adults. However, the use of sterile occlusive dressings is 
recommended for children and has been shown to result 
in fewer exit site infections in this group of patients.
The abdomen should be dry and prophylactic antibiotics • 
should be given before invasive procedure involving 
the abdomen or pelvis (e.g. PD catheter fluoroscopy, 
colonoscopy, renal transplant or endometrial biopsy) or 
extensive dental procedures.
Patients should be instructed on the importance of • 
regular bowel habits and avoidance of constipation; 
a high fiber diet may be helpful but laxatives (e.g. 
lactulose, macrogols) are often required.
To reduce the incidence of fungal peritonitis, patients • 
should receive prophylactic fluconazole with every 
antibiotic course of two weeks duration or more. 
Nystatin is a second line alternative to fluconazole.
Management of exit site and tunnel infections
Exit site infection is defined by the presence of purulent • 
drainage with or without erythema at the catheter-
epidermal interface. A scoring system was developed 
for monitoring the exit site. Infection should be assumed 
with an exit site score of 4 or greater; however, purulent 
discharge is enought by itself to diagnose exit site 
infection (Table 1). 
Isolated peri-catheter erythema is often a simple skin • 
reaction to trauma, but may also be an early sign of 
infection. Ask the patient about accidental catheter 
trauma in the past few days. Advice the patient to 
perform exit site care twice daily using povidone iodine 
followed by dilute hydrogen peroxide, and to avoid 
occlusive dressing. Any worsening should be reported 
immediately, and reassessment by the PD team should 
be arranged within one week.
Positive culture in the absence of abnormal appearance • 
at the exit site is indicative of colonization rather than 
infection. More intensive exit site care is sufficient.
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Tunnel infection is characterized by erythema, edema • 
or tenderness over the subcutaneous pathway, but can 
be clinically occult. Tunnel infection usually occurs in 
the presence of an exit site infection and rarely occurs 
alone. During examination of the catheter exit site, the 
catheter tract should be milked to see if any drainage 
is present and observed for evidence of erythema 
overlying the tunnel. 
Staphylococcus aureus•  and Pseudomonas aeruginosa 
exit site infection are very often associated with 
concomitant tunnel infection, and these are the 
organisms that most often result in catheter infection 
related peritonitis; aggressive management is always 
indicated for these organisms.
Exit site infections can be managed initially by PD • 
nurses using appropriate protocols. If a clinical diagnosis 
of exit site and/or tunnel infection is made, take a swab 
from the drainage for Gram stain and culture. Start 
empiric oral therapy with amoxicillin, cephalexin, 
or clarithromycin unless Gram negative infection is 
suspected, in which case oral ciprofloxacin should be 
used. Avoid ciprofloxacin in children less than 12 years 
old and use intraperitoneal (IP) ceftazidime instead. 
The exit site should be cleaned twice daily in case of • 
infection. If exit site infection is particularly severe, 
apply hypertonic saline dressings twice daily in addition 
to antibiotic therapy. The procedure involves adding 1 
table spoon of salt to 500 ml of sterile water, applying 
this solution to gauze and wrapping it around the exit 
site for 15 minutes.
Modify treatment according to culture results. Treatment • 
should continue for at least seven days after resolution 
of all signs of infection, with a minimum total duration 
of two weeks. Treatment with two antibiotics, including 
ciprofloxacin, is indicated for Pseudomonas aeruginosa 
infections, with the addition of IP ceftazidime if the 
infection resolves slowly or recurs. Removal of the 
catheter is indicated if fungal infection is confirmed to 
prevent progression to fungal peritonitis.
If the infection persists after two weeks of antibiotic • 
therapy:
Ascertain that the patient is complying with the • 
therapeutic regimen.
Re-examine the catheter for evidence of tunnel • 
infection. An ultrasound scan should be performed 
to exclude a small abscess formation along the 
tunnel tract. 
An exposed external cuff should be completely • 
shaved off under local anesthetic with debridement 
of the surrounding tissue to help clear the 
infection. 
Another two weeks of antibiotic therapy may • 
be attempted provided that infection has not 
progressed, no abscess is present, and any exposed 
cuff has been trimmed. 
The catheter should be removed if the infection • 
has progressed despite two weeks of antibiotic 
therapy, an abscess is present, fungal infection has 
been confirmed, or peritonitis has developed. 
Catheter removal should be via surgical dissection rather • 
than traction to avoid retention of the cuffs. Antibiotics 
should be continued for one to two weeks after catheter 
removal. If the patient does not have peritonitis, a new 
catheter can be placed simultaneously in the opposite 
lower quadrant. PD may be resumed immediately, 
initially in the supine position. 
Diagnosis of PD related peritonitis
Assume peritonitis in all patients presenting with cloudy • 
effluent, and attempt to confirm it by obtaining effluent 
cell count, differential, and culture. Consider the 
possibility of peritonitis in any PD patient presenting 
with abdominal pain, fever, nausea or general ill health 
even if the effluent is clear.
To prevent delay in treatment, peritonitis can be managed • 
initially by PD nurses using appropriate protocols. 
Table 1: Exit site scoring system
0 point 1 point 2 points
Swelling No < 0.5 cm (exit only) > 0.5 cm (or tunnel)
Crust No < 0.5 cm > 0.5 cm
Redness No < 0.5 cm > 0.5 cm
Pain No Slight Severe
Drainage No Serous Purulent*
* purulent drainage is diagnostic of exit site infection, even if isolated.
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Start antibiotic therapy as soon as cloudy effluent is seen • 
and a sample of the effluent has been taken, without 
waiting for confirmation by the cell count from the 
laboratory. In a suspected case of peritonitis, carefully 
inspect the exit site and the tunnel of the catheter for 
evidence of catheter infection; culture any drainage 
from the exit site along with the effluent. 
Patients who reside in remote locations should report • 
symptoms suggestive of peritonitis immediately to the 
center, keep the cloudy effluent bag until they are able 
to bring in the sample for analysis, and possibly initiate 
IP antibiotics at home.
Send the whole bag to the microbiology department • 
(preferably the first bag noticed to contain a 
cloudy effluent) and request effluent cell count and 
differential, gram stain, and culture. Effluent white 
blood cells (WBC) more than 100/µL, with at least 
50% polymorphonuclear neutrophil cells, confirm the 
diagnosis of peritonitis.  Gram stain is important in that 
it may indicate the presence of fungi, thus allowing for 
prompt initiation of antifungal therapy and permitting 
timely arrangement of catheter removal. With this 
exception, empiric therapy should not be based on the 
Gram stain, but should follow the protocol as outlined 
below. A positive culture in the absence of a significant 
WBC count represents contaminants and should not be 
considered as peritonitis.
To attain the highest possible culture yield, centrifuge 50 • 
ml of peritoneal effluent at 3000 g for 15 minutes, mix 
the sediment in 3–5 ml of sterile saline and inoculate 
this material both on solid culture media (incubated in 
aerobic, micro-aerophilic, and anaerobic environments) 
and into a standard blood culture medium. If equipment 
for centrifuging large amounts of fluid is not available; 
inject 5–10 ml of effluent directly into blood culture 
bottles. If blood culture bottles and centrifugation 
equipment are not available; shake the bag manually, 
take 5 ml of effluent and inoculate in solid culture 
media. Store the whole bag in an incubator to encourage 
growth and test the effluent daily if feasible.
Treatment principles and steps
Relieve pain using paracetamol and opioid analgesics • 
(e.g. tramadol, morphine, pethidine) for patients with 
significant residual renal function (RRF). Use NSAIDs 
for patients without significant RRF (e.g. Ibuprofen, 
diclofenac).
Start empirical IP treatment with a first and third • 
generation cephalosporin (e.g. cefazolin plus 
ceftazidime). Aminoglycosides can be used as 
alternatives to third generation cephalosporins for gram 
negative coverage if third generation cephalosporins 
are not available. 
Aminoglycoside use carries the risk of irreversible • 
cochlear and vestibular ototoxicity especially with 
large doses, prolonged or frequent administration and 
increasing age. To reduce this risk, use intermittent IP 
dosing.
The above regimen is recommended for pediatric • 
patients unless the child has fever, severe abdominal 
pain, or a risk factor for severe infection (e.g. history 
of MRSA infection, recent or current evidence of PD 
catheter infection, exit site or nasal colonization with 
Staphylococcus aureus, or age less than 2 years). In such 
cases use vancomycin or teicoplanin in combination 
with a third generation cephalosporin as initial therapy
Patients with extremely cloudy effluent may benefit • 
from heparinization of the dialysate (500 units of 
heparin per liter) to prevent occlusion of the catheter 
by fibrin. Refrain from using concentrated fluids during 
episodes of peritonitis. 
Within 48 hours of initiating therapy, most patients • 
will show considerable clinical improvement and the 
effluent will be visibly clearing. By this time the initial 
culture results should have come allowing treatment to 
be modified accordingly. If there is no improvement 
after 48 hours, consider placing the patient on IPD for 
24 hours in an attempt to clear the effluent. Then, keep 
the abdomen dry for 2-3 days apart from a single daily 
exchange with antibiotics. There is some evidence that 
white cells in peritoneum function better in the absence 
of any dialysate. 
After 72 hours of initiating therapy, repeat peritoneal • 
effluent WBC count and differential. If the infection 
is resolving, continue treatment for two weeks and 
change the transfer set after completion of therapy. If 
the effluent WBC count reveals that the infection is not 
resolving and the first culture result remains negative 
at 72 hours, send another effluent sample for culture 
and consider the possibility of fungal or mycobacterial 
peritonitis. Continue with the initial antibiotic regimen 
for another two days. 
Assess the patient at day five, if he/she has improved, • 
leave the catheter in place. Modify the antibiotics 
according to culture results or continue with the initial 
regimen if the second culture is also negative. Continue 
treatment for at least two weeks and change the transfer 
set after completion of therapy.
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If the patient has not improved by day five and the • 
second culture is positive, modify the antibiotics 
according to the second culture results. Assess the 
patient after another five days and remove the catheter 
if there is still no clinical improvement. 
If the patient has not improved by day five and the • 
second culture is also negative, remove the catheter 
and change the antibiotic regimen to vancomycin plus 
gentamicin. Continue treatment for at least two weeks.
Total duration of therapy should be at least two weeks. • 
Peritonitis due to Staphylococcus aureus, Gram 
negative organisms, or enterococci should be treated for 
a minimum duration of 3 weeks whether the catheter 
was removed or not. 
Peritonitis due to • Pseudomonas aeruginosa should 
always be treated with a combination of two antibiotics. 
Peritonitis due to fungal organisms (diagnosed by • 
microscopy or culture) mandates immediate catheter 
removal preceded by peritoneal lavage until the effluent 
is clear to avoid the formation of adhesion and lower the 
fungal burden. 
Fluconazole for four weeks (initially IP), is the drug of • 
choice for fungal peritonitis. For patients with severe 
infections and those who have had significant prior 
exposure to azole antifungals, add amphotericin B (test 
dose required) until the culture results are available 
with susceptibilities.
Mycobacterial peritonitis should be suspected in any • 
patient with prolonged failure to thrive, prolonged 
symptoms despite antibiotic therapy, or relapsing 
peritonitis with negative bacterial cultures.
Indications for catheter removal 
When indicated, early catheter removal is crucial • 
to reduce the mortality and morbidity. The primary 
goal should always be optimal patient treatment and 
protection of the peritoneum, and not saving the catheter. 
Prolonged attempts to treat refractory peritonitis are 
associated with extended hospital stay, peritoneal 
membrane damage, and, in some cases, death. Death 
related to peritonitis, defined as death of a patient 
with active peritonitis, or admitted with peritonitis, or 
within 2 weeks of a peritonitis episode, should be a very 
infrequent event.
The catheter should be removed in the following • 
conditions: fungal peritonitis, refractory peritonitis, 
relapsing peritonitis, catheter related peritonitis, 
peritonitis related to an intra-abdominal pathology, and 
refractory exit site or tunnel infection (Table 2).
If the catheter is removed because of relapsing peritonitis • 
and the effluent has rapidly cleared, simultaneous 
catheter placement can be attempted. In case of 
refractory or fungal peritonitis, a minimum period of 
4 weeks is recommended between the time of catheter 
removal and placement of a new catheter.
It is preferred to re-insert PD catheters surgically or • 
laparoscopically following an episode of peritonitis 
because of the risk of adhesions. The catheter should 
also be sutured into the pelvis at the first attempt of 
reinsertion.
Preventing recurrence of peritonitis
Every episode of peritonitis should be perceived • 
as a potentially preventable event and thoroughly 
investigated by the PD team. 
Table 2: Terminology of peritonitis
Recurrent peritonitis An episode that occurs within 4 weeks of completion of therapy of a prior episode but with a different 
organism
Relapsing peritonitis An episode that occurs within 4 weeks of completion of therapy of a prior episode with the same 
organism or one sterile episode
Repeat peritonitis An episode that occurs more than 4 weeks after completion of therapy of a prior episode with the 
same organism
Refractory peritonitis Failure of the effluent to clear after 5 days of appropriate antibiotics therapy
Catheter related peritonits Peritonitis in conjunction with an exit-site or tunnel infection with the same organism or one site 
sterile
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Enquire from the patient carefully and in a non-• 
threatening manner about the possible mechanism of 
the episode (e.g. poor aseptic technique, lack of clean 
area to carry out exchanges, poor eyesight, recent 
exit-site infection, constipation or diarrhea) and advice 
accordingly. 
Re-train patients and arrange for a home visit after each • 
episode of peritonitis, home visits are invaluable in 
detecting errors in the technique.
Following each episode of peritonitis, fill out the • 
Sudan-PD unified peritonitis questionnaire. 
Drug delivery 
With strict adherence to aseptic technique, IP • 
administration of antibiotics and antifungal agents is 
preferred to IV administration. IP antibiotics can be 
given in each exchange (continuous dosing) or once 
daily (intermittent dosing). 
Continuous dosing is preferred for inpatient treatment, • 
while intermittent dosing is preferred for outpatient 
treatment (Tables 3 and 4). 
In intermittent dosing, the antibiotic-containing • 
dialysis solution must be allowed to dwell for at 
least 6 hours (utilizing the night exchange) to allow 
adequate absorption of the antibiotic into the systemic 
circulation. 
Vancomycin, aminoglycosides and cephalosporins can • 
be mixed in the same dialysis solution bag without loss 
of bioactivity. However, aminoglycosides should not be 
added to the same exchange with penicillins because of 
chemical incompatibility. 
For any antibiotics that are to be mixed, separate • 
syringes must be used for adding the antibiotics. Some 
antibiotics are incompatible if combined in the same 
syringe but compatible when mixed in dialysis solutions, 
e.g. vancomycin and ceftazidime (1 liter or higher).
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Table 3: Recommendations for IP antibiotic dosing for anuric adult CAPD patients (increase dose by 25% for patients producing 
more than 100 ml of urine daily)
Generic name Intermittent
(one exchange per day)
Continuous
(all exchanges, mg per liter)
Amikacin 2 mg/kg LD 25, MD 12
Amoxicillin ND LD 250-500, MD 50
Amphotericin  ND MD 1.5
Ampicillin ND MD 125
Ampicillin/sulbactam    2 g every 12 hours LD 1000, MD 100
Aztreonam ND LD 1000, MD 250
Azlocillin ND LD 500, MD 250
Cefazolin  15 mg/kg LD 500, MD 125
Ceftazidime 1-1.5 g LD 500, MD 125
Ceftizoxime 1 g LD 250, MD 125
Cephalothin 15 mg/kg LD 500, MD 125
Cephradine  15 mg/kg LD 500, MD 125
Cifepime 1 g LD 500, MD 125
Ciprofloxacin ND LD 50,   MD 25
Clindamycin ND LD 300, MD 125
Fluconazole 200 mg NA
Gentamicin 0.6 mg/kg* LD 8, MD 4
Imipenem/cilastatin 1 g bd LD 500, MD 200
Nafcillin ND MD 125
Netilmicin 0.6 mg/kg LD 8, MD 4
Oxacillin ND MD 125
Penicillin G ND LD 50000, MD 25000 units
Teicoplanin 15 mg/kg LD 400, MD 40 **
Tobramycin 0.6 mg/kg LD 8, MD 4
Vancomycin 30 mg/kg every 5-7 days *** LD 1000, MD 25
* Check blood level every 3-4 days (target 2-4 mg/l), if level < 2 mg/l increase dose by 0.2 mg/kg, if level > 4 mg/l reduce dose by 0.2 mg/kg, 
if level > 7 mg/l miss a day and reduce dose by 0.2 mg/kg.
** In each bag for 7 days, then in 2 bags/day for 7 days, then in 1 bag/day for 7 days.
*** Check blood level on day 4 (target > 10 mg/l), if level < 12 mg/l repeat dose every 5 days, if level 13-14 mg/l repeat dose every 6 days, 
if level > 15  mg/l repeat dose every 7 days (usual dose for anuric patients). 
LD: loading dose in mg, MD: maintenance dose, ND: no data, NA: not applicable
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Table 4: Recommendations for IP antibiotic dosing for adult APD patients
Generic name Intermittent dosing for APD patients (long dwell)
Cefazolin 20 mg/kg once daily
Cifepime 1 g once daily
Fluconazole 200 mg once daily every 24-48 hours
Tobramycin 1.5 mg/kg loading dose then 0.5 mg/kg once daily
Vancomycin 30 mg/kg loading dose then 15 mg/kg once daily every 3-5 days
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Algorithm 1 
Management of Exit Site Infection




Management of PD Related Peritonitis
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Algorithm 3  
Management of PD Related Culture Negative Peritonitis




Management of Fungal Peritonitis
